ArticleNeuroscience2018
Effects of Chronic Oxytocin Administration and Diet Composition on Oxytocin and Vasopressin 1a Receptor Binding in the Rat Brain.
Article in Neuroscience, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 38 citations in OpenAlex.
- Intranasal Oxytocin for Obesity.NEJM evidence · 2024Trial
- Melanocortin agonism in a social context selectively activates nucleus accumbens in an oxytocin-dependent manner.Neuropharmacology · 2024Article
- Novel Long-Acting Oxytocin Analog with Increased Efficacy in Reducing Food Intake and Body Weight.International journal of molecular sciences · 2022Article
- Oxytocin as a potential pharmacological tool to combat obesity.Journal of neuroendocrinology · 2022Review
- Developmental exposure to intranasal vasopressin impacts adult prairie vole spatial memory.Psychoneuroendocrinology · 2022Article
- Effects of Intranasal Administration of Oxytocin and Vasopressin on Social Cognition and Potential Routes and Mechanisms of Action.Pharmaceutics · 2022Review
- Robust Reductions of Body Weight and Food Intake by an Oxytocin Analog in Rats.Frontiers in physiology · 2021Article
- Effects of Combined Oxytocin and Beta-3 Receptor Agonist (CL 316243) Treatment on Body Weight and Adiposity in Male Diet-Induced Obese Rats.Frontiers in physiology · 2021Article
- Oxytocin as an Anti-obesity Treatment.Frontiers in neuroscience · 2021Review
- Oxytocin receptor binding in the titi monkey hippocampal formation is associated with parental status and partner affiliation.Scientific reports · 2020Article
- Metabolic Effects of Oxytocin.Endocrine reviews · 2020Review
- The role of oxytocin in regulation of appetitive behaviour, body weight and glucose homeostasis.Journal of neuroendocrinology · 2020Review
- Oxytocin Ameliorates Impaired Behaviors of High Fat Diet-Induced Obese Mice.Frontiers in endocrinology · 2020Article
- Oxytocin improves probabilistic reversal learning but not effortful motivation in Brown Norway rats.Neuropharmacology · 2019Article
- Nanoparticle encapsulation increases the brain penetrance and duration of action of intranasal oxytocin.Hormones and behavior · 2019Article
- Nonclassical Islet Peptides: Pancreatic and Extrapancreatic Actions.Clinical medicine insights. Endocrinology and diabetes · 2019Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 2 institutions in 1 country.
Funding
Abstract
Oxytocin (OT) elicits weight loss in diet-induced obese (DIO) rodents, nonhuman primates, and humans, in part, by reducing food intake. Chronic OT administration produces more sustained weight loss in high-fat diet (HFD)-fed DIO rodents relative to chow-fed controls, but the reasons for this effect remain unclear. We hypothesized that HFD-induced obesity is associated with elevated OT receptor (OXTR) binding in brain regions where OT is known to cause decreased food intake and that this sensitized neural system is one mechanism by which OT preferentially elicits weight loss in DIO rodents. We therefore determined the impact of diet (HFD vs chow) and drug treatment (chronic OT infusion vs vehicle) on (1) OXTR binding in hindbrain and forebrain sites where OT suppresses food intake relative to control sites that express OXTR and (2) forebrain vasopressin 1a receptor (AVPR1a) density to evaluate the specificity of any OT effects. Using quantitative receptor autoradiography, we found that (1) diet composition failed to alter OXTR or AVPR1a binding; (2) chronic OT treatment produced largely global reductions in forebrain OXTR and AVPR1a binding without significantly altering hindbrain OXTR binding. These findings suggest that forebrain OXTR and AVPR1a are down-regulated in response to chronic OT treatment. Given that chronic intranasal OT may be used as a therapeutic strategy to treat obesity, future studies should consider the potential downregulatory effect that chronic treatment can have across forebrain and hindbrain nonapeptide receptors and assess the potential contribution of both receptor subtypes to the outcome measures.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.